Article Information
History
- January 31, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Markus Hoffmann1,*,†,
- Hannah Kleine-Weber1,2,†,
- Nadine Krüger3,4,
- Marcel Müller5,6,
- Christian Drosten5,6 and
- Stefan Pöhlmann1,2,*
- 1Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research, Göttingen, Germany
- 2Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany
- 3Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany
- 4Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany
- 4Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany
- 5German Centre for Infection Research, associated partner Charité, Berlin, Germany
- 6Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, Moscow, Russia
- ↵*Corresponding authors. E-mail: mhoffmann{at}dpz.eu (M.H.), spoehlmann{at}dpz.eu (S.P.)
↵† These authors contributed equally
Posted January 31, 2020.
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
